Web of Pharma · Cleaning Validation · GMP Risk Control
Cleaning Validation MACO, PDE and HBEL Calculation
A practical, risk-based guide to toxicological limits, carryover calculations, surface limits, swab and rinse acceptance criteria, and audit-ready cleaning-validation decisions.
answer
MACO is the maximum allowable carryover of a previous product into the next product. In a modern cleaning-validation program, the limit is normally derived from a toxicologically justified PDE or HBEL, then converted into equipment-surface, swab, and rinse limits. Legacy approaches such as 10 ppm or 1/1000th of a therapeutic dose may be used only when scientifically justified and aligned with the applicable quality system; they should not replace a suitable health-based assessment.
Cleaning-validation calculations translate toxicological knowledge into an operational limit that a manufacturing team can test. The calculation must protect the patient, preserve product quality, remain achievable by the cleaning process, and be measurable by a validated analytical method.
MACO, PDE, and HBEL are related but different concepts. PDE or HBEL describes an acceptable health-based exposure to a substance. MACO converts that exposure into the maximum mass of residue that may remain on shared equipment before the next product is manufactured. Swab and rinse limits then convert the equipment-level value into sample-level acceptance criteria.
This article explains the calculation logic, unit conversions, worked examples, legacy approaches, worst-case selection, sampling, documentation, and review expectations. It should be used with your approved Process Validation in Pharmaceuticals lifecycle, Cleaning Validation in Pharmaceuticals program, and cGMP quality system.
What Do MACO, PDE, and HBEL Mean?
| Term | Meaning | Role in cleaning validation |
|---|---|---|
| MACO | Maximum Allowable Carryover: the maximum mass of residue from a previous product that may carry into the next product. | Converts a toxicological or quality limit into an equipment-level carryover limit. |
| PDE | Permitted Daily Exposure: a substance-specific daily exposure unlikely to cause appreciable harm when considered through an appropriate toxicological assessment. | Often serves as the health-based starting point for residue-limit calculations. |
| HBEL | Health-Based Exposure Limit: an exposure limit derived from pharmacological and toxicological evaluation, such as a PDE or an equivalent scientifically justified value. | Supports risk identification and cross-contamination control in shared facilities. |
| Surface limit | The allowable residue expressed per unit of shared product-contact surface, commonly µg/cm². | Creates a measurable limit for equipment mapping and swab sampling. |
| Swab/rinse limit | The allowable residue in a defined swab area or rinse sample volume. | Allows laboratory results to be compared with the calculated acceptance criterion. |
How PDE and HBEL Are Established
A PDE or HBEL assessment reviews the pharmacology and toxicology of the previous product and identifies an exposure level appropriate for the relevant route, patient population, and cross-contamination scenario. The calculation should be traceable to the source data and should explain uncertainty.
Define the substance
Confirm active, metabolite, intermediate, degradation product, impurity, cleaning agent, and relevant route of exposure.
Review data
Evaluate clinical, nonclinical, pharmacological, toxicological, reproductive, genotoxic, immunological, and sensitization information.
Select point of departure
Identify a suitable NOAEL, LOAEL, benchmark, clinical exposure, or other scientifically justified starting point.
Apply factors
Apply appropriate uncertainty, interspecies, intraspecies, exposure-duration, severity, and data-quality factors.
Consider route and population
Assess oral, inhalation, dermal, parenteral, pediatric, reproductive, and other route-specific concerns where relevant.
Document uncertainty
Explain limitations, data gaps, critical assumptions, and any additional protective rationale.
Approve the HBEL
Obtain qualified toxicology and quality approval before using the value in MACO or cleaning decisions.
Review lifecycle data
Reassess when new safety information, formulation changes, routes, products, or regulatory expectations arise.
Core PDE-Based MACO Formula
For carryover of previous product A into the next product B, a commonly used PDE-based relationship is:
The formula assumes the residue from product A is distributed into the next batch of product B and that the selected dose and batch-size inputs represent the intended worst-case relationship. The calculation should be supported by a product-pair matrix and a documented rationale for the chosen values.
Unit discipline
- Convert minimum batch size to the same mass unit used in the formula, usually mg.
- Use the maximum daily dose of the next product B, not the previous product's dose.
- Record whether the dose is expressed as active substance, finished product, or dosage form mass.
- Use the PDE/HBEL of the residue being controlled, including route or population assumptions.
- Keep the calculation sheet traceable, reviewed, version-controlled, and protected from accidental changes.
Worked Example: PDE-Based MACO
Assume product A has an approved PDE of 0.001 mg/day. Product B has a minimum batch size of 10 kg and a maximum daily dose of 1,000 mg/day.
MACO = 0.001 mg/day × 10,000,000 mg ÷ 1,000 mg/day
MACO = 10 mg of product A residue in the shared equipment train
That 10 mg is the equipment-level carryover limit before it is converted into a surface or sample limit. It does not mean that 10 mg may be intentionally left on equipment. The cleaning procedure should normally achieve a result comfortably below the acceptance limit and should also meet visual, microbial, detergent, and product-quality requirements.
Convert the MACO into a surface limit
If the total shared product-contact surface area is 25,000 cm²:
Surface limit = 0.4 µg/cm²
Convert the surface limit into a swab limit
If the validated swab area is 100 cm²:
Theoretical swab limit = 40 µg per swabApply the validated recovery correction and reporting convention before comparing the laboratory result with this limit.
Convert the MACO into a rinse limit
If the final representative rinse volume is 20 L:
Theoretical rinse limit = 0.5 mg/LRinse sampling must demonstrate that the selected volume and locations represent the equipment and cleaning process.
Legacy 10 ppm and Therapeutic-Dose Calculations
Older cleaning-validation programs often use a 10 ppm limit or a fraction of a therapeutic dose. These approaches can be useful as historical comparison points, but they are not automatically protective for every active, route, or product pair. A health-based assessment should be considered first, and the site should document how conflicting limits are resolved.
10 ppm approach
For a 50 kg minimum batch of product B:
MACO10 ppm = 500 mg
In the worked PDE example, the PDE-based result was 10 mg, so the PDE-based limit is more stringent than 500 mg. This illustrates why 10 ppm should not be assumed to be sufficiently protective for a potent or toxicologically sensitive product.
Therapeutic-dose approach
A legacy dose-based method may be expressed conceptually as:
With a previous-product dose of 200 mg/day, a 10 kg next batch, a next-product maximum daily dose of 1,000 mg/day, and a 1,000-fold safety factor:
MACOdose = 2,000 mg
For the same 10 kg next batch, the 10 ppm comparison would be 100 mg. Compared with the PDE result of 10 mg, the dose-based result is the least stringent in this example. The final limit should follow the approved regulatory and toxicological rationale, not whichever formula gives the largest number.
Choosing the Worst-Case Product and Product Pair
Cleaning-validation worst-case selection is not based on PDE alone. A product with a low PDE may be toxicologically challenging, while another product with a higher PDE may be much harder to remove or may create a lower MACO because of the next product's dose and batch size.
Low PDE or HBEL
Lower health-based exposure limits generally reduce the allowable carryover and may drive the product-pair calculation.
Low solubility
Poorly soluble residues may require stronger chemistry, longer contact time, mechanical action, or specialized cleaning verification.
High adhesion
Sticky, oily, particulate, or pigment-containing formulations may be difficult to remove from product-contact surfaces.
High potency or sensitization
Potent, sensitizing, genotoxic, or highly active substances can require tighter controls and specialist toxicology review.
Small next batch
A small minimum batch size can produce a lower MACO because the same residue is diluted into less next-product mass.
High next-product dose
A high maximum daily dose of the next product can reduce the permissible carryover under the PDE equation.
Large shared surface
A large product-contact area can lower the allowable residue per cm² even when the total MACO is unchanged.
Difficult equipment geometry
Dead legs, valves, gaskets, screens, transfer lines, and spray shadows may challenge cleaning and sampling.
Stability or degradation
Persistent, reactive, or degradation-prone residues may require specific analytical targets and additional cleaning controls.
Surface, Swab, and Rinse Limit Calculations
Once the equipment-level MACO is approved, convert it into sample limits that match the validated sampling plan. The calculation must use the actual or justified product-contact surface area and the sampling method's recovery characteristics.
| Limit | Conceptual calculation | Key control |
|---|---|---|
| Surface residue limit | MACO (mg) × 1,000 µg/mg ÷ total shared product-contact area (cm²) | Surface-area map must include the shared product-contact equipment train. |
| Swab sample limit | Surface limit (µg/cm²) × validated swabbed area (cm²) | Apply the approved recovery correction and report the result using the validated method. |
| Rinse sample limit | MACO (mg) ÷ representative final rinse volume (L) | Rinse volume, location, recovery, solubility, and equipment drainage must be justified. |
| Detergent limit | Based on toxicology, product quality, cleaning-agent specification, and validated method capability. | Do not assume the active-residue MACO applies to detergent or excipient residues. |
| Microbial/endotoxin limit | Based on product, process, route, facility, water system, and microbiological risk. | Chemical MACO does not replace microbial or endotoxin controls. |
Cleaning Validation Sampling and Analytical Methods
MACO is only useful when the sampling and analytical methods can reliably detect residue at the calculated limit. A method that cannot recover or quantify the target at the acceptance criterion creates a verification gap.
Map equipment
Identify product-contact surfaces, hard-to-clean locations, drain paths, transfer lines, valves, seals, and dead legs.
Select swab points
Choose locations by risk, accessibility, residue behavior, geometry, and cleaning difficulty.
Plan rinse points
Use representative rinse volumes, locations, and conditions when direct swabbing is impractical or incomplete.
Complete recovery study
Demonstrate recovery from representative surfaces using the actual swab, solvent, technique, and laboratory method.
Validate specificity
Show that product, detergent, excipient, surface, and degradation residues do not create misleading results.
Confirm sensitivity
Verify LOQ, linearity, precision, accuracy, stability, and suitability around the acceptance limit.
Set visual checks
Use visual cleanliness as an additional requirement; it does not replace chemical or microbiological testing.
Trend routine data
Review cleaning verification results, recurring locations, failures, and changes throughout the equipment lifecycle.
HPLC, UV, TOC, conductivity, pH, specific chemical assays, microbiological tests, and endotoxin methods may be appropriate depending on the residue and risk. TOC is not automatically suitable for every compound; demonstrate that the target residue contains measurable oxidizable carbon and that the method is fit for purpose.
Cleaning-Validation Calculation Workflow
Use this sequence to move from a toxicological value to an approved cleaning-validation limit.
Define the previous product
Identify active, strength, residue form, route, toxicology, solubility, stability, and cleaning behavior.
Define the next product
Confirm minimum batch size, maximum daily dose, route, dosage form, and product-quality risks.
Approve PDE/HBEL
Use an approved toxicological assessment and record assumptions, uncertainty, and review date.
Calculate MACO
Apply the PDE-based relationship and verify all units, product-pair inputs, and arithmetic.
Compare legacy limits
Assess 10 ppm or therapeutic-dose calculations only where the approved approach requires them.
Choose the protective limit
Document the final value and why it protects health, quality, and applicable expectations.
Convert to samples
Use equipment surface area, swab area, rinse volume, recovery, and reporting conventions.
Verify and maintain
Approve the protocol, validate cleaning, investigate failures, and reassess after relevant changes or new data.
Cleaning Validation Documentation and Data Integrity
Calculations are regulated evidence. They should be controlled like any other validation record and linked to the cleaning-validation protocol, equipment drawings, toxicology report, analytical method, recovery study, sampling plan, and final report.
Calculation sheet
Record formulas, units, inputs, product pair, surface area, batch size, dose, PDE/HBEL source, reviewer, revision, and approval.
Product-pair matrix
Show how limits change across previous and next products, strengths, batch sizes, shared equipment, and cleaning campaigns.
Equipment map
Document the product-contact surface area and the swab/rinse locations used to represent the equipment train.
Recovery evidence
Link each sample result to validated recovery, surface type, swab, solvent, operator technique, and laboratory method.
Electronic controls
Protect formulas, access, audit trails, version history, backups, and report reproducibility in validated systems.
Change review
Reassess limits after new toxicology, formulation, dose, equipment, supplier, route, or cleaning-process information.
Use ALCOA+ principles for original, attributable, contemporaneous, accurate, complete, consistent, enduring, and available calculation evidence. Electronic records and signatures should be assessed against applicable 21 CFR requirements.
Deviations, Failures, and CAPA
A cleaning-validation failure may arise from the cleaning procedure, residue selection, sampling, recovery, analytical method, equipment design, operator technique, calculation, or data system. Investigate the complete chain before deciding that the cleaning process alone failed.
| Signal | First questions | Possible response |
|---|---|---|
| Swab above MACO | Was the location representative? Was the sample correctly identified, recovered, stored, and tested? | Contain equipment, assess product impact, investigate cleaning and sampling, and repeat only under an approved procedure. |
| Rinse passes but swab fails | Is the residue localized, poorly soluble, or hidden in a hard-to-clean location? | Review surface mapping, cleaning mechanics, swab recovery, equipment geometry, and cleaning parameters. |
| Visual residue observed | Could residue be visible but below the chemical method's quantitation limit? | Fail visual criterion, investigate, and do not release equipment solely on a numerical result. |
| Detergent residue | Are detergent limits and analytical methods defined separately from active-residue MACO? | Assess cleaning-agent dose, rinsing, method suitability, and product-quality impact. |
| Repeated location failure | Does the trend indicate equipment geometry, cleaning access, technique, or procedure weakness? | Open a systemic investigation and connect required actions to CAPA new and the established CAPA process. |
Do not change the MACO, surface area, recovery factor, sample location, or reporting rule after seeing an unfavorable result unless the change is scientifically justified, controlled, approved, and assessed for its effect on previously generated evidence.
Qualification and Cleaning-Process Readiness
Cleaning calculations cannot compensate for an unqualified equipment or facility. Confirm that the equipment design, installation, operation, performance, cleaning cycle, utilities, and data systems are ready before beginning validation.
Requirements
Define cleaning intent, residue risks, equipment surfaces, cycle parameters, sampling, and acceptance needs in the URS.
Design
Assess cleanability, drainability, materials, dead legs, spray coverage, access, and hygienic design through DQ.
Installation
Verify equipment, piping, instruments, labels, utilities, and product-contact materials through IQ.
Operation
Challenge cleaning-cycle parameters, alarms, recipes, controls, and operating ranges through OQ.
Performance
Demonstrate reproducible cleaning under routine and justified worst-case conditions through PQ.
Procedure
Control cleaning steps, hold times, sampling, deviations, equipment status, and operator training through an approved SOP.
Audit-Ready MACO, PDE, and HBEL Checklist
- Previous and next products, routes, strengths, batch sizes, doses, and shared equipment are clearly identified.
- PDE/HBEL values come from an approved toxicological assessment with source data, assumptions, factors, and review date.
- The previous-product PDE/HBEL and next-product maximum daily dose are not accidentally reversed.
- Minimum next-batch size is converted into consistent mass units before the MACO calculation.
- Product-pair matrix considers the combination that creates the most protective or operationally challenging limit.
- 10 ppm and therapeutic-dose limits are treated as justified comparison methods, not automatic universal requirements.
- Total shared product-contact surface area is calculated from an approved equipment map.
- Swab area, rinse volume, recovery factor, sample handling, and reporting units are defined and validated.
- Visual, detergent, microbial, endotoxin, and product-quality criteria are addressed separately where applicable.
- Analytical method specificity, accuracy, precision, recovery, LOQ, stability, and data integrity support the limit.
- Deviations, failures, OOS/OOT, changes, and repeat testing are controlled by approved procedures.
- MACO, PDE/HBEL, equipment, cleaning, and product knowledge are reassessed through the lifecycle.
Key Takeaways
PDE/HBEL comes first
Start with a qualified health-based assessment before converting exposure into carryover.
MACO is product-pair specific
The previous product, next product, batch size, daily dose, route, and equipment all affect the result.
Units must be controlled
Convert kg, g, mg, µg, cm², L, and mL consistently and verify every formula before approval.
10 ppm is not universal
Legacy limits should be scientifically justified and compared with health-based results.
Sampling completes the calculation
Surface, swab, and rinse limits must match validated recovery and representative sampling.
Protect the lifecycle
Review new toxicology, products, equipment, cleaning failures, and changes through CAPA and change control.
Conclusion
Cleaning Validation MACO, PDE, and HBEL Calculation is a bridge between toxicology and practical GMP cleaning control. PDE or HBEL establishes a health-based exposure boundary; MACO converts that boundary into an equipment-level residue limit; surface, swab, and rinse calculations make the limit testable.
The most defensible program controls the entire chain: qualified toxicology, product-pair risk assessment, correct units, accurate surface mapping, validated recovery and analytical methods, visual and microbiological controls, complete data, and proportionate investigations. Treat 10 ppm and therapeutic-dose formulas as legacy comparison tools unless your approved scientific and regulatory strategy supports them. A clear rationale is more valuable than a copied number.
Related Pharmaceutical Quality Guides
Frequently Asked Questions
1. What is MACO in cleaning validation?
MACO is the maximum allowable carryover of residue from a previous product into a subsequent product. It is commonly calculated from the previous product's PDE or HBEL, the next product's minimum batch size, and the next product's maximum daily dose.
2. What is the PDE-based MACO formula?
A commonly used relationship is: MACO (mg) = PDE of previous product (mg/day) × minimum batch size of next product (mg) ÷ maximum daily dose of next product (mg/day). Keep all units consistent and document the product-pair rationale.
3. What is the difference between PDE and HBEL?
PDE is a specific health-based daily exposure value derived from toxicological and pharmacological information. HBEL is a broader term for a health-based exposure limit, which may be expressed as a PDE or another scientifically justified value.
4. Is 10 ppm still an acceptable cleaning limit?
10 ppm is a legacy approach and is not automatically protective for every active or product pair. Compare it with the approved health-based assessment and document the scientific and regulatory rationale for the final limit.
5. What is the 1/1000th therapeutic-dose method?
It is a legacy dose-based approach that applies a safety factor to a selected therapeutic daily dose of the previous product and the maximum daily dose of the next product. The site must define the dose convention and should not use the method without a justified quality and toxicology rationale.
6. How is MACO converted to a swab limit?
First convert MACO to a surface limit using the total shared product-contact area. Then multiply the surface limit by the validated swabbed area and apply the approved recovery correction or reporting convention.
7. How is MACO converted to a rinse limit?
Divide the equipment-level MACO by a representative final-rinse volume to obtain a theoretical rinse concentration. The rinse volume, sampling location, residue solubility, recovery, and analytical method must be justified.
8. Who should approve a PDE or HBEL?
A suitably qualified toxicologist or health-based exposure-limit subject-matter expert should perform or approve the assessment, with Quality involvement and documented review of assumptions, uncertainty, route, and patient population.
9. Does visual inspection replace MACO testing?
No. Visual inspection is an important additional criterion, but it cannot generally demonstrate absence of invisible residue at a health-based limit. Chemical, microbiological, detergent, and endotoxin controls may also be required.
10. When should MACO or HBEL calculations be reassessed?
Reassess after new toxicology or clinical data, a product or dose change, a new route, formulation or supplier change, equipment or site change, cleaning failure, new product introduction, or a regulatory or quality-risk review.
.webp)
